# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-25T21:18:39.366452

---

**Idea Fidelity**

The paper largely adheres to the manifest. It uses Eurostat S11 sector accounts for 27 EU countries, focuses on interest-to-operating-surplus and debt composition ratios, and exploits ATAD variation via de minimis thresholds and staggered adoption. The dose-response DiD and placebo strategies described in the manifest are implemented, though the paper omits explicit use of EBITDA cap variation and quantitative treatment of derogation timing beyond the placebo—these are mentioned but not fully operationalized. The data sources, summary statistics, and motivation align closely with the original idea.

**Summary**

This paper evaluates whether the EU ATAD I interest limitation rule shifted aggregate corporate financing toward equity, using country-year Eurostat data for 2012–2023. The author exploits cross-country variation in de minimis thresholds (dose) and staggered adoption to estimate DID effects on the interest-to-operating-surplus ratio, debt composition, and leverage. The results show no statistically or economically significant aggregate response, and the design is argued to be sufficiently powered to rule out moderate effects.

**Essential Points**

1. **Identification and Pre-Trend Evidence Need Strengthening:** The dose-response strategy hinges on comparability across dose groups, yet the narrative acknowledges that low-threshold countries may have had pre-existing strict rules. The event study shown pools all countries but does not graphically or statistically differentiate dose strata. I recommend plotting the event study separately for high- and low-dose groups or interacting dose with time trends pre-2019 to verify parallel trends. Without this, the identifying assumption is susceptible to confounding by pre-existing heterogeneity.

2. **Treatment Intensity Definition and Interpretation Are Underdeveloped:** The “dose” variable simply scales de minimis thresholds linearly from 0 to 1, but the economic relevance of moving from €5M to €0 is not transparent. Why should this gradient be linear? Do countries with low thresholds also differ systematically on other margins (e.g., existing thin-cap rules)? Please justify the functional form, consider alternative codings (e.g., log threshold bins, indicator for zero threshold), and explore whether the dose variable predicts treatment intensity empirically (e.g., share of firms affected) to bolster the causal interpretation.

3. **Power Calculations and Null Interpretation Need Nuance:** The claim that the study “rules out” effects larger than 5 percentage points is feasible, but the argument for policy relevance of smaller effects is not fully articulated. Five percentage points is already a sizable shift in aggregate interest burden. Please report confidence intervals, discuss whether such moderate effects would matter for macro-financial stability, and temper the language around “null” results—consider framing them as “not detectably larger than X” rather than “no effect.”

**Suggestions**

1. **Expand the Dose-Response Specification:** Instead of a single linear dose interaction, consider estimating non-linear effects by interacting adoption with spline terms or threshold indicators (e.g., €0–1M, €1–3M, €3–5M). This would reveal whether the constraint only bites at the bottom end and would mitigate concerns about arbitrary scaling. You can also interact the dose variable with country characteristics (size, pre-existing thin cap) to control for potential confounders.

2. **Differentiate Sources of Variation:** The manifest highlighted both de minimis thresholds and variation in EBITDA caps/derogation timing. The paper currently treats EBITDA cap variation only in passing (Appendix). Incorporating a robustness table that interacts the main specification with a “strict cap” indicator or runs subsample analyses (strict vs. standard cap countries) would improve completeness. Similarly, you can exploit the staggered timing more directly—e.g., by focusing on the 6 derogation countries as late-treated units and estimating dynamic effects around their actual adoption (2022/2024), rather than only using them in a placebo.

3. **Graphical Diagnostics:** Include plots of the key ratios over time by dose quartile (or simple binary threshold groups). Visual evidence would help readers assess whether treated and control countries follow similar trends pre-2019. Additionally, show the counterfactual path implied by the FE model alongside the raw data to contextualize the null result.

4. **Heterogeneity and Mechanisms:** The discussion mentions that tight thresholds may still behave differently because countries had existing rules. Consider exploring heterogeneity by corporate debt share or by the size of the non-financial corporate sector relative to GDP. You could also test whether the reform affected cross-border debt (if data allow) or whether firm-level results (from other studies) can be reconciled with the null aggregate finding by, for example, demonstrating that the share of firms affected is small.

5. **Treatment Exposure Measure:** Aggregate ratios implicitly weight countries equally, ignoring differences in sector size. Re-estimate using weighted regressions (e.g., GDP-weighted or share of EU non-financial debt) to see if results change. If large economies with generous thresholds drive the aggregate path, the unweighted approach may mask meaningful effects for the euro-area scale.

6. **Clarify Standard Errors and Inference:** The wild cluster bootstrap results are helpful, but some readers may question the small number of clusters. Report p-values for the main coefficients using both methods in the main regression table, and comment on how inference changes (if at all). Also, provide the degrees of freedom for the bootstrap (number of clusters) to aid reproducibility.

7. **Policy Interpretation Caveats:** The policy discussion currently suggests that the null result indicates “phantom correction” and points toward ACE as an alternative. While plausible, note that aggregate data may hide distributional effects: ATAD may meaningfully constrain the largest multinationals’ leverage even if aggregate ratios stay flat. Frame policy implications accordingly—emphasize that ATAD’s macro impact appears limited but firm-level compliance could still be effective.

8. **Data Transparency:** Provide, ideally in an online appendix, the exact coding of de minimis thresholds and adoption dates for each country along with the constructed dose variable. This would help other researchers replicate the analysis and assess the variation.

In sum, the paper tackles an important policy question with a novel dataset and a clearly articulated design. Tightening the identification checks, enriching the dose-response treatment, and clarifying the substantive interpretation of the null result will strengthen the contribution substantially.
